Editor’s note: This is a developing news story. Please check back soon for updates.
Tenpoint Therapeutics submitted a new drug application to the FDA for Brimochol PF, an eye drop for presbyopia treatment, according to a press release.
Brimochol PF (carbachol/brimonidine tartrate fixed-dose combination) is a combination therapy designed to sharpen near and distant images and improve depth of focus by producing a pinhole effect.
The submission is supported by positive data from the phase 3 BRIO-I and BRIO-II studies. In BRIO-I, the combination therapy demonstrated benefit over the